Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.11.009
Abstract: OBJECTIVES Pembrolizumab is recommended for patients with previously untreated non-small cell lung cancer (NSCLC) with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of ≥1%. The KEYNOTE-024 study described the efficacy of pembrolizumab… read more here.
Keywords: efficacy pembrolizumab; previously untreated; group; lung cancer ... See more keywords
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003868
Abstract: Background Chemoradiation therapy (CRT) has been increasingly reported as a possible alternative to total cystectomy (TC) for localized bladder cancer (BC). Pembrolizumab is the standard of care for platinum-refractory metastatic urothelial carcinoma, although it is… read more here.
Keywords: efficacy pembrolizumab; crt recurrent; previously treated; crt ... See more keywords
PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC.
Sign Up to like & getrecommendations! Published in 2020 at "Chinese clinical oncology"
DOI: 10.21037/cco.2020.01.03
Abstract: The introduction of programmed death-1 (PD-1) and the programmed death-ligand 1 (PD-L1) inhibitors have significantly impacted cancer therapy over a relatively short period of time. Within the past 5 years, the PD-1/PD-L1 inhibitors have become… read more here.
Keywords: efficacy pembrolizumab; line; study; expression ... See more keywords